Perspective Therapeutics (NYSE:CATX) Upgraded to Strong-Buy at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Perspective Therapeutics (NYSE:CATX - Free Report) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Perspective Therapeutics' FY2024 earnings at ($0.90) EPS and FY2025 earnings at ($1.09) EPS.

Several other brokerages have also issued reports on CATX. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Oppenheimer cut their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a research note on Friday, November 22nd. Bank of America cut shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Finally, Wedbush restated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Friday, January 24th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $15.13.

Remove Ads

Perspective Therapeutics Trading Down 3.3 %

CATX stock traded down $0.09 during mid-day trading on Tuesday, hitting $2.61. 466,490 shares of the stock were exchanged, compared to its average volume of 843,163. The business has a fifty day moving average price of $3.21 and a 200 day moving average price of $7.71. Perspective Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.05.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new position in Perspective Therapeutics during the 4th quarter valued at about $33,000. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $34,000. National Bank of Canada FI raised its holdings in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after acquiring an additional 10,998 shares in the last quarter. ProShare Advisors LLC lifted its stake in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after acquiring an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. bought a new stake in Perspective Therapeutics in the fourth quarter valued at $51,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.